Pacific Biosciences of California Cost of Revenue 2011-2026 | PACB

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.

What is included in the cost of revenue

Cost Category	Examples
Production Costs	Materials, wages of production staff, depreciation of equipment
Service and Support	Customer service, user support, technical assistance
Delivery and Logistics	Packaging, delivery of goods to customers
Hosting and Infrastructure	Servers, cloud platforms (especially for IT and SaaS companies)
Content and Licenses	License purchases, production royalties (e.g., in streaming services)

Importance of the Metric

Helps to understand how costly the revenue-generating process is.
A high cost of revenue may indicate:
Poor cost control
Low operational efficiency
A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Annual Cost of Revenue Pacific Biosciences of California

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
114 M	117 M	148 M	79.3 M	71.7 M	46.3 M	56.3 M	53.5 M	58.8 M	46.6 M	39.3 M	37.2 M	21.8 M	25 M	20.8 M	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
148 M	20.8 M	62.4 M

Quarterly Cost of Revenue Pacific Biosciences of California

2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
24.3 M	22.5 M	25.1 M	38.5 M	-	30 M	30.1 M	27.5 M	-	37.8 M	32 M	29.1 M	-	18.8 M	19.3 M	19 M	-	19.5 M	16.9 M	16 M	-	12 M	10.5 M	8.11 M	-	15 M	15 M	11.3 M	-	15 M	12.7 M	12.1 M	-	15.3 M	12.1 M	16 M	-	12.5 M	10.1 M	9.62 M	-	7.37 M	10.4 M	11.7 M	-	7.46 M	8.3 M	8.97 M	-	6.18 M	4.99 M	4.65 M	-	2.59 M	7.02 M	10.2 M	-	7.19 M	2.73 M	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
38.5 M	2.59 M	15.4 M

Cost of Revenue of other stocks in the Diagnostics research industry

Issuer	Cost of Revenue	Price	% 24h	Market Cap	Country
Centogene N.V. CNTG	162 M	-	-6.23 %	$ 30.6 M	Germany
Co-Diagnostics CODX	222 K	$ 1.32	-19.02 %	$ 1.76 M	USA
Agilent Technologies A	2.91 B	$ 112.31	-0.84 %	$ 34.1 B	USA
Castle Biosciences CSTL	71 M	$ 19.54	3.5 %	$ 566 M	USA
Akumin AKU	608 M	-	-17.87 %	$ 25.9 M	Canada
Fulgent Genetics FLGT	176 M	$ 15.85	-2.1 %	$ 479 M	USA
Aspira Women's Health AWH	3.3 M	-	-6.19 %	$ 10.5 M	USA
Accelerate Diagnostics AXDX	9.45 M	-	-61.36 %	$ 2.46 M	USA
Biocept BIOC	28.4 M	-	-13.05 %	$ 7.29 M	USA
Illumina ILMN	1.51 B	$ 140.5	-1.91 %	$ 22.3 B	USA
Interpace Biosciences IDXG	14.6 M	$ 1.8	-	$ 7.96 M	USA
CareDx, Inc CDNA	45.5 M	$ 19.85	-3.12 %	$ 1.06 B	USA
Chembio Diagnostics CEMI	38.6 M	-	0.22 %	$ 16.8 M	USA
HTG Molecular Diagnostics HTGM	4.57 M	-	-20.0 %	$ 1.06 M	USA
Lantheus Holdings LNTH	600 M	$ 94.39	-2.36 %	$ 6.37 B	USA
Global Cord Blood Corporation CO	183 M	-	-	$ 399 M	China
Myriad Genetics MYGN	248 M	$ 3.63	0.14 %	$ 336 M	USA
Genetic Technologies Limited GENE	276 K	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	194 M	-	0.12 %	$ 80.1 M	China
NeoGenomics NEO	413 M	$ 8.28	-0.96 %	$ 1.06 B	USA
DermTech DMTK	15 M	-	-11.32 %	$ 2.94 M	USA
Natera NTRA	158 M	$ 187.81	-4.62 %	$ 18.5 B	USA
Enzo Biochem ENZ	17.3 M	-	-8.98 %	$ 14.8 K	USA
Exact Sciences Corporation EXAS	984 M	-	-	$ 19.8 B	USA
Koninklijke Philips N.V. PHG	9.78 B	$ 25.3	-0.82 %	$ 24 B	Niderland
Guardant Health GH	349 M	$ 93.62	-5.11 %	$ 11.7 B	USA
Personalis PSNL	53.9 M	$ 6.53	-2.68 %	$ 583 M	USA
Heska Corporation HSKA	146 M	-	-	$ 1.31 B	USA
Senseonics Holdings SENS	19.5 M	$ 5.74	-1.37 %	$ 240 M	USA
ICON Public Limited Company ICLR	3.97 B	$ 117.02	-0.06 %	$ 9.65 B	Irlanda
Soleno Therapeutics SLNO	2.7 M	$ 52.99	-	$ 2.69 B	USA
QIAGEN N.V. QGEN	801 M	-	-	$ 10.6 B	Niderland
Biomerica BMRA	4.81 M	$ 2.33	-3.32 %	$ 5.35 M	USA
Laboratory Corporation of America Holdings LH	9.94 B	$ 251.91	-0.83 %	$ 21 B	USA
Trinity Biotech plc TRIB	40.1 M	$ 0.56	-3.84 %	$ 201 M	Irlanda
Motus GI Holdings MOTS	81 K	-	-34.28 %	$ 263 K	Israel
Twist Bioscience Corporation TWST	186 M	$ 49.5	-6.52 %	$ 2.96 B	USA
Neogen Corporation NEOG	473 M	$ 8.28	-1.84 %	$ 1.8 B	USA
Quest Diagnostics Incorporated DGX	7.37 B	$ 187.84	-0.05 %	$ 20.9 B	USA
Invitae Corporation NVTA	92.8 M	-	-	$ 21.2 M	USA